HCG vs gonadorelin vs enclomiphene — the TRT-adjunct decision tree

That gap is worth closing.

The three approaches to preserving HPG axis function during TRT — or to supporting endogenous testosterone production without TRT at all — are HCG, gonadorelin, and enclomiphene. They work at different levels of the axis, they produce different hormonal profiles, and they fit different clinical situations. Understanding the distinction between them requires holding the axis itself in mind: the hypothalamus produces GnRH, the pituitary produces LH and FSH, the testes produce testosterone. Exogenous testosterone suppresses this chain by telling the hypothalamus that enough testosterone is present, shutting down GnRH, which shuts down the gonadotropins, which silences the testes.

The three adjuncts address this suppression at three different points.

HCG, as covered in more depth elsewhere, acts at the bottom of the chain — directly on the LH receptor in the Leydig cells of the testes. It bypasses the hypothalamus and pituitary entirely and tells the testes directly to keep producing testosterone and, critically, to maintain the intratesticular testosterone concentrations that spermatogenesis requires. HCG does not restore the axis — the pituitary is still suppressed, the hypothalamus is still suppressed — but it prevents the atrophy and functional dormancy that would otherwise follow from that suppression. The testes remain active because HCG is providing the stimulus the pituitary is no longer sending.

This directness is HCG's primary advantage. The mechanism is well-characterized, the clinical experience spans decades, and it is reliably effective at maintaining testicular volume and spermatogenesis in the men who need it. The protocols are straightforward: 250 to 500 IU subcutaneously, two to three times per week. The pharmacokinetics are favorable — HCG's half-life of 24 to 36 hours means meaningful Leydig cell stimulation is maintained with that dosing frequency without daily injections. The fertility-preservation data is the strongest available among the three options. For men who are actively pursuing conception while on TRT, HCG has the most clinical validation behind it.

The primary drawback of HCG is its effect on estradiol. Leydig cell activation driven by HCG stimulates steroidogenesis broadly — not just testosterone synthesis but aromatase activity, which converts testosterone to estradiol. Men on HCG alongside TRT often see estradiol rise above what TRT alone would produce. This isn't universally a problem, and in some cases elevated estradiol is neutral or even beneficial — estradiol has its own role in male physiology, including libido and bone density. But in some men it contributes to fluid retention, gynecomastia, or mood effects that require management, sometimes with an aromatase inhibitor alongside the HCG. The monitoring requirement is real.

The second limitation is FSH. HCG binds the LH receptor with high affinity but has minimal FSH receptor activity. In men whose fertility concerns include FSH-dependent aspects of spermatogenesis — specifically Sertoli cell support, which FSH governs — HCG alone may not fully address the picture. This is particularly relevant in men with more severe spermatogenic impairment where FSH coverage matters. Some providers add recombinant FSH in these cases. Others consider gonadorelin as an alternative or complement that stimulates the pituitary's own FSH production.

Gonadorelin works higher in the axis — at the level of the pituitary, rather than the testes. Synthetic GnRH delivered in pulses stimulates the pituitary gonadotroph cells to produce LH and FSH, which then travel to the testes and carry out their normal functions. Where HCG says "here is your LH signal — act on it," gonadorelin says "here is your GnRH signal — make your own LH and FSH." The pituitary does the intermediate work. Both gonadotropins are produced. The Leydig cells receive LH and produce testosterone. The Sertoli cells receive FSH and support spermatogenesis. The downstream effects are more complete, at least in theory, because both arms of gonadal stimulation are engaged.

The argument for gonadorelin over HCG is strongest where FSH matters — in fertility-focused protocols where spermatogenesis needs full support, not just intratesticular testosterone maintenance. It's also argued, on theoretical grounds, that stimulating the pituitary rather than bypassing it preserves more of the axis's architecture. Whether that translates into long-term clinical advantages — better recovery when TRT stops, better hormonal resilience — is not established in robust comparative trials. The argument is biologically coherent. The data is limited.

The practical problem with gonadorelin is the pharmacokinetics. GnRH has a serum half-life measured in minutes. Meaningful pituitary stimulation requires frequent dosing — some protocols use twice-daily subcutaneous injections. This is less convenient than HCG's two-to-three-times-per-week schedule, and adherence is a real consideration in a protocol that already requires TRT injections. The dosing also needs to remain pulsatile in character — continuous GnRH receptor stimulation produces downregulation and suppression rather than stimulation, which is the pharmacological principle behind GnRH agonist therapy. The practical implementation of pulse-frequency dosing with a short-half-life peptide is more demanding than it sounds.

Gonadorelin has also faced supply and regulatory variability in the compounding context, affecting its availability at different times and in different regions. When compounded HCG has been difficult to obtain, some providers have shifted to gonadorelin, generating clinical experience that has built provider familiarity. The comparative data between the two remains limited; most of what exists is retrospective clinical observation rather than head-to-head trials.

Enclomiphene is structurally different from both — it is not a peptide, not an injectable, and not a hormone or hormone analog. It is an oral selective estrogen receptor modulator, a SERM. Enclomiphene is the trans-isomer of clomiphene citrate — the fertility drug that has been used in women for decades — isolated from the racemic mixture because the other isomer (zuclomiphene) has longer-lasting estrogenic effects that complicate the picture. Enclomiphene, in isolation, acts as a pure estrogen receptor antagonist in the hypothalamus and pituitary.

The mechanism is upstream of everything else: estrogen normally provides negative feedback to the hypothalamus, suppressing GnRH pulsatility. Block the estrogen receptor at the hypothalamus, and the hypothalamus reads estrogen as low, increases GnRH pulsatility, and drives the pituitary to release more LH and FSH — ramping the entire intact axis from the top down. This makes enclomiphene well suited to men optimizing natural testosterone without TRT, or recovering the axis after stopping it, rather than to use during ongoing TRT where testosterone and estrogen are already elevated.

Laid out as a practical decision tree, the three tools sort by goal rather than by preference. For a man who wants to preserve fertility while staying on TRT, HCG is the usual first move — the track record is deepest and the dosing is the most manageable, with gonadorelin or added recombinant FSH reserved for cases where FSH-dependent spermatogenesis needs more support than LH-receptor stimulation alone provides. For a man optimizing his own testosterone without TRT at all, enclomiphene is the better fit, because it drives an intact axis from the top. And for a man coming off TRT and trying to restart his own production, the approaches are often sequenced rather than chosen — HCG first to wake up testes that have gone dormant, followed by a SERM such as enclomiphene to push the recovering hypothalamic-pituitary signal back online. None of these are off-the-shelf protocols; each is calibrated to baseline labs, semen analysis where conception is the goal, and tolerance of side effects like estradiol elevation, which is precisely the work a prescribing provider does.

The through-line across all three is the same: the right tool is the one that matches the level of the axis you are trying to support and the goal you are actually after — HCG at the testes, gonadorelin at the pituitary, enclomiphene at the hypothalamus — which makes the choice a matching exercise that belongs with a prescribing provider working from your labs and your fertility plans rather than a default.